Article
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Haematologica - 1 Mar 2017
Cortes Jorge, Talpaz Moshe, Smith Hedy P, Snyder David S, Khoury Jean, Bhalla Kapil N, Pinilla-Ibarz Javier, Larson Richard, Mitchell David, Wise Scott C, Rutkoski Thomas J, Smith Bryan D, Flynn Daniel L, Kantarjian Hagop M, Rosen Oliver, Van Etten Richard A
Abstract excerpt
A vailable tyrosine kinase inhibitors for chronic myeloid leukemia bind in an adenosine 5'-triphosphate-binding pocket and are affected by evolving mutations that confer resistance. Rebastinib was identified as a switch control inhibitor of BCR-ABL1 and FLT3 and may be active against resistant mutations. A Phase 1, first-in-human, single-agent study investigated rebastinib in relapsed or refractory chronic or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.